PMID- 21703176
OWN - NLM
STAT- MEDLINE
DCOM- 20120521
LR  - 20231213
IS  - 1600-0641 (Electronic)
IS  - 0168-8278 (Linking)
VI  - 56
IP  - 1
DP  - 2012 Jan
TI  - Interleukin-28B genetic variants in identification of hepatitis C virus genotype 
      1 patients responding to 24 weeks peginterferon/ribavirin.
PG  - 34-40
LID - 10.1016/j.jhep.2011.03.029 [doi]
AB  - BACKGROUND & AIMS: A substantial proportion of hepatitis C virus genotype 1 
      (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA 
      seronegative throughout 24 weeks of post-treatment follow-up) after 24 weeks 
      peginterferon/ribavirin therapy. We explored the role of interleukin-28B genotype 
      in identifying patients who responded to the regimen. METHODS: Interleukin-28B 
      rs8099917 genotype was determined in 226 HCV-1 patients with 24 weeks 
      peginterferon/ribavirin. RESULTS: Compared to patients with rs8099917 TG/GG 
      genotype, those with TT genotype had significantly higher rapid virological 
      response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, 
      p<0.001) and SVR (64.7% vs. 25.6%, p<0.001) rates, and lower relapse rate (28.0% 
      vs. 54.5%, p=0.01). Logistic regression analysis revealed that the strongest 
      factor predictive of a RVR was the carriage of rs8099917 TT genotype (odds ratio/ 
      95% confidence intervals [OR/CI]: 6.24/2.34-16.63), followed by lower viral loads 
      (OR/CI: 5.29/2.81-9.93) and age (OR/CI:0.94/0.91-9.97). The most important factor 
      predictive of an SVR was the attainment of a RVR (OR/CI: 22.23/9.22-53.58), 
      followed by the carriage of rs8099917 TT genotype (OR/CI: 3.38/1.18-9.65), lower 
      viral loads (OR/CI: 2.23/1.00-4.93) and ribavirin exposure dose (OR/CI: 
      1.17/1.06-1.30). The determinant power of rs8099917 genotype on SVR was mainly 
      restricted to non-RVR patients, particularly those with higher baseline viral 
      loads. Combination of the two pretreatment predictors, interleukin-28B genotype 
      and baseline viral loads, could predict treatment efficacy with a positive 
      predictive value of 80% and a negative predictive value of 91%. CONCLUSIONS: 
      Interleukin-28B genotype could help identifying patients who are or are not 
      candidates for an abbreviated regimen before treatment.
CI  - Copyright (c) 2011 European Association for the Study of the Liver. Published by 
      Elsevier B.V. All rights reserved.
FAU - Huang, Chung-Feng
AU  - Huang CF
AD  - Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical 
      University Hospital, Kaohsiung, Taiwan.
FAU - Huang, Jee-Fu
AU  - Huang JF
FAU - Yang, Jeng-Fu
AU  - Yang JF
FAU - Hsieh, Ming-Yen
AU  - Hsieh MY
FAU - Lin, Zu-Yau
AU  - Lin ZY
FAU - Chen, Shinn-Cherng
AU  - Chen SC
FAU - Wang, Liang-Yen
AU  - Wang LY
FAU - Juo, Suh-Hang Hank
AU  - Juo SH
FAU - Chen, Ku-Chung
AU  - Chen KC
FAU - Chuang, Wan-Long
AU  - Chuang WL
FAU - Kuo, Hsing-Tao
AU  - Kuo HT
FAU - Dai, Chia-Yen
AU  - Dai CY
FAU - Yu, Ming-Lung
AU  - Yu ML
LA  - eng
PT  - Journal Article
DEP - 20110519
PL  - Netherlands
TA  - J Hepatol
JT  - Journal of hepatology
JID - 8503886
RN  - 0 (Antiviral Agents)
RN  - 0 (interferon-lambda, human)
RN  - 0 (Interferon-alpha)
RN  - 0 (Interleukins)
RN  - 0 (Recombinant Proteins)
RN  - 49717AWG6K (Ribavirin)
RN  - 9008-11-1 (Interferons)
SB  - IM
EIN - J Hepatol. 2012 May;56(5):1218
EIN - J Hepatol. 2012 May;56(5):1218. PMID: 32898985
MH  - Adult
MH  - Antiviral Agents/administration & dosage
MH  - Female
MH  - *Genetic Variation
MH  - Genotype
MH  - Hepacivirus/classification/drug effects/*genetics
MH  - Hepatitis C, Chronic/*drug therapy/*genetics/immunology/virology
MH  - Humans
MH  - Interferon-alpha/*administration & dosage
MH  - Interferons
MH  - Interleukins/*genetics
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide
MH  - Recombinant Proteins/administration & dosage
MH  - Ribavirin/*administration & dosage
MH  - Treatment Outcome
MH  - Viral Load/drug effects
EDAT- 2011/06/28 06:00
MHDA- 2012/05/23 06:00
CRDT- 2011/06/28 06:00
PHST- 2011/01/11 00:00 [received]
PHST- 2011/03/03 00:00 [revised]
PHST- 2011/03/25 00:00 [accepted]
PHST- 2011/06/28 06:00 [entrez]
PHST- 2011/06/28 06:00 [pubmed]
PHST- 2012/05/23 06:00 [medline]
AID - S0168-8278(11)00376-X [pii]
AID - 10.1016/j.jhep.2011.03.029 [doi]
PST - ppublish
SO  - J Hepatol. 2012 Jan;56(1):34-40. doi: 10.1016/j.jhep.2011.03.029. Epub 2011 May 
      19.